Navigation Links
Mylan Launches First Generic Version of Xibrom® Ophthalmic Solution
Date:5/16/2011

PITTSBURGH, May 16, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Bromfenac Ophthalmic Solution, 0.09% (Twice Daily Administration), based on a development and supply agreement with Coastal Pharmaceuticals. This product is the first generic version of ISTA's Xibrom® Ophthalmic Solution, 0.09% (Twice Daily Administration), a treatment for postoperative inflammation in patients who have undergone cataract extraction.

Bromfenac Ophthalmic Solution had U.S. sales of approximately $116 million for the 12 months ending March 31, 2011, according to IMS Health.

Currently, Mylan has 169 ANDAs pending FDA approval representing $100.7 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $25.8 billion in annual brand sales, for the 12 months ending Dec. 31, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
(Date:3/27/2017)... Texas , March 27, 2017   Genprex, Inc. , ... that Julien Pham , MD, the Company,s Chief Operating Officer, ... investor conferences. Sachs 5th Annual Cancer BioPartnering & ... New York, NY ... BioCentury 24th Annual Future Leaders in ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 ... Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone stimulators ... $724 million by 2022, growing at a CAGR of 3.6% during the forecast ... ... Allied Market Research Logo ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be commonplace ... injury, it occurs when the muscles around the pelvis become inflamed. Over time, ... lower torso, as well as accompanying tenderness and weakness. Without proper intervention, it ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... simulation -centric training, today announced the launch of a new research study, The ... the skills needed to execute that strategy, and the actual success of achieving ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... announce that for a second year in a row; they are the recipient ... designers in the industry voted on the award at Design Connections 2017. Top ...
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still in shock ... the best days I’ve had in a long time,” she said. , She thinks the ... of money that I never thought I would have to help my students.” , The ...
(Date:3/27/2017)... ... ... The Anaheim Hills office accelerates and supports FNCC’s growth and further strengthens ... professionals over the past 6 months and is continuing to recruit new talent with ... of 2017. , “This new office is a direct result of our strong ...
Breaking Medicine News(10 mins):